- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 29.07. | Quoin picks its cornerstone, shelving 2 assets to build around lead program | ||
| 29.07. | Bausch Health bags phase 3-ready liver prospect in $63M Durect buyout | ||
| 29.07. | BMS hands 5 autoimmune drugs to new spinout backed by $300M in Bain-led funding | ||
| 29.07. | AstraZeneca drops lead T-cell receptor therapy from $200M Neogene buy | ||
| 28.07. | Arrowhead says beleaguered Sarepta has 60 days to pay $100M in milestone | ||
| 28.07. | Adaptimmune sells 4 cell therapies to pharma for $55M, plans layoffs | ||
| 28.07. | MapLight raises $373M to plot phase 2 journey for would-be rival to BMS' Cobenfy | ||
| 28.07. | Boehringer eyes $1B deal to use Re-Vana's drug delivery tech on ophthalmic pipeline | ||
| 28.07. | Atai's schizophrenia drug fails to improve cognition in phase 2 study | ||
| 28.07. | Celcuity's breast cancer combo hits primary endpoints, teeing up FDA filing | ||
| 28.07. | GSK strengthens COPD offering via $12B biobucks, 12-program deal with China's Hengrui Pharma | ||
| 25.07. | Chinese antibody developer Leads Biolabs hits Hong Kong stock exchange in $189M IPO | ||
| 25.07. | BMS names AstraZeneca's Cristian Massacesi as new chief medical officer | ||
| 25.07. | 'We will crack gene therapy': Elevidys fallout doesn't dent Roche's hopes for modality | ||
| 25.07. | Memo pushes kidney drug to phase 3 despite primary endpoint miss | ||
| 24.07. | Brandon Capital raises $290M for its largest life sciences fund yet | ||
| 24.07. | Lilly opens Gate to new small molecule drug class with $856M biobucks deal | ||
| 24.07. | Novartis puts $1B on the line to court preclinical biotech Matchpoint | ||
| 24.07. | Galapagos builds island of cell therapies to prep for potential sale amid pipeline pruning | ||
| 24.07. | Cell therapy biotech Adicet turns to autoimmune, shedding a phase 1 asset and 30% of staffers | ||
| 24.07. | Rocket adjusts trajectory, laying off 30% of staff and narrowing pipeline focus | ||
| 24.07. | AstraZeneca's blockbuster contender hits phase 3 goals, fueling myasthenia gravis fight | ||
| 24.07. | Roche axes Carmot obesity asset, 3 cancer drugs in R&D clear-out | ||
| 23.07. | Genentech eliminates 87 jobs in another round of South San Francisco layoffs | ||
| 23.07. | With $550M on the line, Arrowhead reassures investors about pact with troubled Sarepta |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .